The 'pharma needs patents because of high costs' argument uses clinical trials as a smokescreen. Clinical trials are a genuine public good imposed by regulation because of a principal-agent problem: firms have a temptation to shade safety results. Public money should therefore fund clinical trials on a competitive basis, for example by redirecting NIH funds, rather than basic research, which produces private goods embodied in labs.
normativepending
Speaker
Michele BoldrinEvidence Quote
“there's no reason to send the NIH money into basic research in my opinion ... the basic research doesn't produce public good it is very private good in the labs”
Created: 10/30/2026, 2:14:15 PM
Your notes
Loading notes...